Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
VOG
Vogenx
VOGX · NASDAQ · Pharmaceutical Preparations · No 10-K yet
No open-market purchase by an insider of Vogenx is on record in SEC filings since 2006.
Who is selling Vogenx stock?
No open-market sale by an insider of Vogenx (VOGX) was filed with the SEC in the last 90 days.
Do members of Congress trade VOGX?
No trade in Vogenx (VOGX) was disclosed by a member of Congress in the last 12 months.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−8.7% (−$1.13) from Aug 12, 2026 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $13.00 on Aug 12, 2026 to $11.87 on Nov 20, 2026 (−8.7%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
$15$20$25$30$35$40$11.87
SepOctNov
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Raleigh, NC. Listed, but no annual report (10-K) filed yet under this SEC registration.
Last 12 months
Not enough history
Market value
$176M
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
Short interest: 74K shares sold short (0.5% of shares outstanding), +93.6% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Latest results: quarter ending Sep 30, 2026
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $5.13M, at Sep 30, 2026
Net income, last 12 months
—
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 6, 2026.
Late-stage clinical trials
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in postbariatric hypoglycemia. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Funds and stakes. William Wilkison now owns 12.9% of VOGX as a passive investor (filed Nov 16, 2026). Richard Bentley Cheatham now owns 5.1% of VOGX as a passive investor (filed Nov 16, 2026). (Vogenx on OQRO)
Contracts, lobbying and filings. ClinicalTrials.gov shows 1 study sponsored by the company updated in the period; the latest, "Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia" (Phase 2, status recruiting), was updated on Nov 5, 2026, with primary completion listed for 2027-10. FINRA short interest for VOGX on the settlement date of Oct 30, 2026 was 74,122 shares (+93.59% on the previous report), about 1 days of average volume.
Company reports, price and press. Vogenx filed a Form 8-K on Nov 6, 2026 (Item 2.02) that OQRO classes as: reported its results. Vogenx filed a Form 8-K on Oct 9, 2026 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Off-exchange trading: 41.1% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (21.0% on ATS, 20.1% with other brokers), below its 9-week average of 50.7%. Weeks of Sep 21 to Oct 16, 2026.
Week of Aug 17ATSOther off-exchange
Nov 13
Affinity Asset Advisors, LLC went above 5%, with 6.2% · Schedule 13G, 2026
Largest ATS: INTELLIGENT CROSS LLC (13.0%), POSIT (10.9%), UBS ATS (10.9%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Since Aug 12, 2026, VOGX is down 8.7% and the index fund is down 10.7%: 2 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much VOGX moves
A usual day
±4.9%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
21.1%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−13.7%Nov 16, 2026
Largest one-day rise
+25.4%Aug 18, 2026
Deepest fall of the year
−65.2%From the close of Sep 17, 2026 to Nov 20, 2026.
Days of 5% or more
35Out of 71 sessions, in either direction.
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
William Wilkison now owns 12.9% of VOGX as a passive investor (filed Nov 16, 2026).
Richard Bentley Cheatham now owns 5.1% of VOGX as a passive investor (filed Nov 16, 2026).
Contracts, lobbying and filings
ClinicalTrials.gov shows 1 study sponsored by the company updated in the period; the latest, "Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia" (Phase 2, status recruiting), was updated on Nov 5, 2026, with primary completion listed for 2027-10.
FINRA short interest for VOGX on the settlement date of Oct 30, 2026 was 74,122 shares (+93.59% on the previous report), about 1 days of average volume.
Company reports, price and press
Vogenx filed a Form 8-K on Nov 6, 2026 (Item 2.02) that OQRO classes as: reported its results.
Vogenx filed a Form 8-K on Oct 9, 2026 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors.
The company's own opening sentence of that report reads: "On October 7, 2026, concurrent with his becoming an employee of Vogenx, Inc. (the 'Company') as Chief Commercial Officer, Richard Gorman resigned from the Board of Directors ('Board') of the Company and from all committees of the..."
Vogenx filed a Form 8-K on Sep 22, 2026 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors.
The company's own opening sentence of that report reads: "On September 21, 2026, the Board of Directors ('Board') of Vogenx, Inc. (the 'Company') appointed Ken Toombs to the Board as a Class II director, to serve until the 2028 annual meeting of stockholders of the Company or until his..."
Press coverage listed by Finnhub: "Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights" (Yahoo, Nov 6, 2026).
Press coverage listed by Finnhub: "Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia" (Yahoo, Oct 15, 2026).
Press coverage listed by Finnhub: "Vogenx Initiates EMERGE, Phase 2b Clinical Trial Evaluating Mizagliflozin For Treatment Of Post-Bariatric Hypoglycemia" (Benzinga, Oct 15, 2026).
VOGX closed at $12.34 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $15.92 to $12.34, a change of −22.5%.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Written by software from the filings listed below · Nov 21, 2026
Funds and stakes. William Wilkison now owns 12.9% of VOGX as a passive investor (filed Nov 16, 2026). Richard Bentley Cheatham now owns 5.1% of VOGX as a passive investor (filed Nov 16, 2026). (Vogenx on OQRO)
Contracts, lobbying and filings. ClinicalTrials.gov shows 1 study sponsored by the company updated in the period; the latest, "Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia" (Phase 2, status recruiting), was updated on Nov 5, 2026, with primary completion listed for 2027-10. FINRA short interest for VOGX on the settlement date of Oct 30, 2026 was 74,122 shares (+93.59% on the previous report), about 1 days of average volume.
Company reports, price and press. Vogenx filed a Form 8-K on Nov 6, 2026 (Item 2.02) that OQRO classes as: reported its results. The press release filed with it is titled: "Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights Advances PBH Development Program Following August 2026 Initial Public Offering Strengthens Balance…"
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
William Wilkison now owns 12.9% of VOGX as a passive investor (filed Nov 16, 2026).
Richard Bentley Cheatham now owns 5.1% of VOGX as a passive investor (filed Nov 16, 2026).
Contracts, lobbying and filings
ClinicalTrials.gov shows 1 study sponsored by the company updated in the period; the latest, "Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia" (Phase 2, status recruiting), was updated on Nov 5, 2026, with primary completion listed for 2027-10.
FINRA short interest for VOGX on the settlement date of Oct 30, 2026 was 74,122 shares (+93.59% on the previous report), about 1 days of average volume.
Company reports, price and press
Vogenx filed a Form 8-K on Nov 6, 2026 (Item 2.02) that OQRO classes as: reported its results.
The press release filed with it is titled: "Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights Advances PBH Development Program Following August 2026 Initial Public Offering Strengthens Balance…"
Its announcing sentence reads: "Vogenx, Inc. (Nasdaq: VOGX), a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced its financial results for the third quarter and provided a corporate update."
Press coverage listed by Finnhub: "Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights" (Yahoo, Nov 6, 2026).
VOGX closed at $11.87 on Nov 20, 2026, the last session on or before the end of the period.
From Oct 21, 2026 to Nov 20, 2026, the close moved from $20.39 to $11.87, a change of −41.8%.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.